Clinical Trial Update: The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating whether Xolair (omalizumab) inhibits the release of leukotrienes and the cytokines IL-4 and IL-13 from blood basophils in in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Diseases

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Creighton University | Conditions: Allergy | Phase 4 | Status: UNKNOWN